Tepkinly:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only.

       

      The first‑and‑only subcutaneous T‑Cell therapy

       

       

      The first‑and‑only subcutaneous T‑Cell therapy

      ADVERSE REACTIONS IN THE EPCORE™ NHL-1 TRIAL

      CRS-related adverse reactions were predictable, manageable, and resolvable

      Predictable:

      95% of CRS events occurred in the first cycle

      Manageable: 

      6.6% adverse event–related discontinuation

      • Discontinuation due to CRS or ICANS occurred in 1 patient each (0.6%)
      • 1 patient (0.6%) experienced a fatal adverse reaction (ICANS)

      Resolvable: 

      CRS resolved in 100%

      • Median duration of CRS events was 2 days (range: 0.1-27 days)

      Predictable:

      95% of CRS events occurred in the first cycle

      Manageable: 

      6.6% adverse event–related discontinuation

      • Discontinuation due to CRS or ICANS occurred in 1 patient each (0.6%)
      • 1 patient (0.6%) experienced a fatal adverse reaction (ICANS)

      Resolvable: 

      CRS resolved in 100%

      • Median duration of CRS events was 2 days (range: 0.1-27 days)

       

      Manageable safety profile

      Only 6.6% of patients discontinued subcutaneous TEPKINLY due to adverse reactions.

       

      Patient experienced ICANS after intermediate dose with multiple confounders, including extensive opioid use for Gr3 pancreatitis, hyperammonemia, multifocal cerebral infarcts in setting of possible microangiopathy, and tocilizumab administration3

      Download the Dosing and Administration Guide for more information on how TEPKINLY is administered.

      DOWNLOAD HERE

      References:

      1. Tepkinly prescribing information 
      2. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238-2247. doi:10.1200/JCO.22.01725
      3. Thieblemont et al abstract LB2364, EHA 2022

       

       

      IL-EPCOR-240017. Date of preparation: July 2024.

       

       

      SCHEDULING TOOL

       

       

      Tepkinly PI – 4mg/0.8ml
      Tepkinly PI – 48 mg